Supernus Pharmaceuticals (NASDAQ:SUPN) was the target of some unusual options trading on Monday. Stock traders acquired 1,861 call options on the stock. This represents an increase of approximately 826% compared to the average volume of 201 call options.
SUPN stock opened at $57.15 on Tuesday. The company has a quick ratio of 4.74, a current ratio of 4.90 and a debt-to-equity ratio of 0.90. The firm has a market cap of $2.95 billion, a price-to-earnings ratio of 37.04 and a beta of 1.14. Supernus Pharmaceuticals has a 52-week low of $55.00 and a 52-week high of $57.40.
Get Supernus Pharmaceuticals alerts:
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.26 by $0.18. The company had revenue of $88.44 million during the quarter, compared to analysts’ expectations of $87.84 million. Supernus Pharmaceuticals had a return on equity of 30.18% and a net margin of 21.89%. equities research analysts anticipate that Supernus Pharmaceuticals will post 1.9 earnings per share for the current fiscal year.
In other news, VP Victor Vaughn sold 17,850 shares of the firm’s stock in a transaction that occurred on Thursday, April 19th. The stock was sold at an average price of $47.93, for a total value of $855,550.50. Following the transaction, the vice president now owns 15,594 shares in the company, valued at $747,420.42. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Padmanabh P. Bhatt sold 67,132 shares of the firm’s stock in a transaction that occurred on Friday, May 11th. The shares were sold at an average price of $53.11, for a total value of $3,565,380.52. Following the completion of the transaction, the vice president now owns 32,500 shares in the company, valued at approximately $1,726,075. The disclosure for this sale can be found here. In the last 90 days, insiders sold 144,982 shares of company stock worth $7,140,731. Company insiders own 6.70% of the company’s stock.
A number of hedge funds have recently bought and sold shares of SUPN. JPMorgan Chase & Co. increased its stake in Supernus Pharmaceuticals by 166.0% during the first quarter. JPMorgan Chase & Co. now owns 461,586 shares of the specialty pharmaceutical company’s stock worth $21,140,000 after acquiring an additional 288,059 shares during the last quarter. Stephens Investment Management Group LLC acquired a new stake in Supernus Pharmaceuticals during the fourth quarter worth $7,316,000. BlackRock Inc. increased its stake in Supernus Pharmaceuticals by 2.5% during the first quarter. BlackRock Inc. now owns 7,071,947 shares of the specialty pharmaceutical company’s stock worth $323,898,000 after acquiring an additional 169,717 shares during the last quarter. Carillon Tower Advisers Inc. acquired a new stake in Supernus Pharmaceuticals during the first quarter worth $7,761,000. Finally, Wells Fargo & Company MN increased its stake in Supernus Pharmaceuticals by 18.6% during the first quarter. Wells Fargo & Company MN now owns 896,110 shares of the specialty pharmaceutical company’s stock worth $41,041,000 after acquiring an additional 140,688 shares during the last quarter. 95.47% of the stock is owned by institutional investors.
A number of equities analysts recently commented on the company. BidaskClub downgraded Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 8th. ValuEngine upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 5th. B. Riley reiterated a “buy” rating and set a $54.00 price objective on shares of Supernus Pharmaceuticals in a research report on Thursday, January 18th. Finally, Berenberg Bank assumed coverage on Supernus Pharmaceuticals in a research report on Thursday, February 1st. They set a “buy” rating and a $66.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $51.36.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy.